Omega-3s, CoQ10 Reduce Colon Cancer Risk

OSLOA new study in the British Journal of Nutrition found daily supplementation with an omega-3 triglyceride (TG) and coenzyme Q10 (CoQ10) may decrease the risk of colon cancer. The randomized, double blind trial, "Effects of EPA, y-linolenic acid or coenzyme Q10 on serum prostate," analyzed the effects of the three ingredients on serum prostate-specific antigen (PSA) levels in healthy Iranian men (Br J Nutr. 2012 Nov 30:1-8).

More than 500 men participated in the study, which assigned subjects to receive either Epax 5500 TG omega-3, Nutri Q10 (100 mg), y-linolenic acid (2,400mg)  or a placebo for 12 weeks. At the end of the trial, Epax users experienced a 30-percent reduction in PSA levels, and CoQ10 dropped levels 33 percent. Y-linolenic acid, on the other hand, increased PSA levels by 15 percent.

In September, Frost & Sullivan honored Epax with its Product Differentiation Excellence Award. Epax, a joint venture between Aker BioMarine and Lindsay Golberg LLC, offers a range e eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) products with European Food Safety Authority (EFSA) claim approval.